A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia.
hepatitis C
injection drug use
nurses
primary care
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
10
11
2021
received:
24
08
2021
accepted:
18
11
2021
pubmed:
26
11
2021
medline:
4
3
2022
entrez:
25
11
2021
Statut:
ppublish
Résumé
Hepatitis C virus (HCV) treatment through primary care and community-based services will be a critical component of HCV elimination. We evaluated a nurse-coordinated programme providing care across eight sites and analysed progression through the HCV care cascade. People-accessing services from six primary care clinics, a homeless crisis accommodation provider and a mental health service were directly referred to nurses or engaged by nurses during regular clinic visits. Nurses supported HCV testing, treatment and follow-up. The prescription was provided by affiliated clinicians. Logistic regression was used to examine factors associated with treatment commencement and sustained virological response (SVR) testing. Of 640 people referred to and/or engaged by the nurses from January 2017 to July 2019, 518 had an HCV RNA test of whom 381 (74%) were HCV RNA positive. Treatment was commenced by 281 (74%) people of whom 161 had an SVR test, 157 (97.5%) were cured. Opioid agonist therapy was associated with treatment commencement (aOR 2.68, 95% CI 1.48-4.88). People who were homeless/unstably housed were less likely to commence treatment (aOR 0.45, 95% CI 0.23-0.87). Treatment prescription from a specialist (aOR 2.39, 95% CI 1.20-4.74) and recent injection drug use (<6 months) (aOR 2.15, 95% CI 1.07-4.31) was associated with SVR testing. A nurse-coordinated model of care led to high levels of HCV treatment uptake and cure amongst people attending primary care and community services. More tailored models of care may be beneficial for people who are homeless or have unstable housing. These results support primary care and community-based hepatitis C treatment.
Sections du résumé
BACKGROUND
Hepatitis C virus (HCV) treatment through primary care and community-based services will be a critical component of HCV elimination. We evaluated a nurse-coordinated programme providing care across eight sites and analysed progression through the HCV care cascade.
METHODS
People-accessing services from six primary care clinics, a homeless crisis accommodation provider and a mental health service were directly referred to nurses or engaged by nurses during regular clinic visits. Nurses supported HCV testing, treatment and follow-up. The prescription was provided by affiliated clinicians. Logistic regression was used to examine factors associated with treatment commencement and sustained virological response (SVR) testing.
RESULTS
Of 640 people referred to and/or engaged by the nurses from January 2017 to July 2019, 518 had an HCV RNA test of whom 381 (74%) were HCV RNA positive. Treatment was commenced by 281 (74%) people of whom 161 had an SVR test, 157 (97.5%) were cured. Opioid agonist therapy was associated with treatment commencement (aOR 2.68, 95% CI 1.48-4.88). People who were homeless/unstably housed were less likely to commence treatment (aOR 0.45, 95% CI 0.23-0.87). Treatment prescription from a specialist (aOR 2.39, 95% CI 1.20-4.74) and recent injection drug use (<6 months) (aOR 2.15, 95% CI 1.07-4.31) was associated with SVR testing.
CONCLUSION
A nurse-coordinated model of care led to high levels of HCV treatment uptake and cure amongst people attending primary care and community services. More tailored models of care may be beneficial for people who are homeless or have unstable housing. These results support primary care and community-based hepatitis C treatment.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
522-531Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192-e1207.
Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030-what will it take to get there? J Int AIDS Soc. 2017;20(1):22146.
Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(3 Suppl 1):112s-s121.
Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350-1359.
Muncan B, Walters SM, Ezell J, Ompad DC. “They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53.
Brener L, von Hippel W, von Hippel C, Resnick I, Treloar C. Perceptions of discriminatory treatment by staff as predictors of drug treatment completion: utility of a mixed methods approach. Drug Alcohol Rev. 2010;29(5):491-497.
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
Cunningham EB, Hajarizadeh B, Amin J, et al. Adherence to once-daily and twice-daily direct-acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. Clin Infect Dis. 2020;71(7):e115-e124.
Wade AJ, Doyle JS, Gane E, et al. Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs. Clin Infect Dis. 2020;70(9):1900-1906.
Oru E, Trickey A, Shirali R, Kanters S, Easterbrook P. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. Lancet Global Health. 2021;9(4):e431-e445.
Palmer AY, Wade AJ, Draper B, et al. A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment. Int J Drug Policy. 2020;76:102633.
Amoako A, Ortiz-Paredes D, Engler K, Lebouché B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: a knowledge synthesis. Int J Drug Policy. 2021;96:103247.
Litwin AH, Drolet M, Nwankwo C, et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE Study. J Viral Hepatitis. 2019;26(9):1094-1104.
Marshall AD, Grebely J, Dore GJ, Treloar C. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience. Drug Alcohol Depend. 2020;206:107705.
Wade AJ, Macdonald DM, Doyle JS, et al. The cascade of care for an Australian community-based hepatitis C treatment service. PLoS One. 2015;10(11):e0142770.
Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust. 2016;204(7):268-272.
Harney BL, Brereton R, Whitton B, et al. Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care. J Viral Hepatitis. 2021;28(5):771-778.
Harney BL, Whitton B, Lim C, et al. Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia. Int J Drug Policy. 2019;72:195-198.
Liu Y, De A. Multiple imputation by fully conditional specification for dealing with missing data in a large epidemiologic study. Int J Stat Med Res. 2015;4(3):287-295.
Eddings W, Marchenko Y. Diagnostics for multiple imputation in Stata. Stata J. 2012;12(3):353-367.
Gamkrelidze I, Pawlotsky J-M, Lazarus JV, et al. Progress towards hepatitis C virus elimination in high-income countries: an updated analysis. Liver Int. 2021;41(3):456-463.
Doyle JS, Scott N, Sacks-Davis R, et al. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia. Aliment Pharmacol Ther. 2019;49(9):1223-1229.
Williams B, Howell J, Doyle J, et al. Point-of-care hepatitis C testing from needle and syringe programs: an Australian feasibility study. Int J Drug Policy. 2019;72:91-98.
Palmer AY, Chan K, Gold J, et al. A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign. J Viral Hepatitis. 2021;28(11):1624-1634.
Chan K, Elsum I, Gold J, et al. Increasing hepatitis C testing and linkage to care: results of a testing campaign with incentives at primary care clinics in Melbourne, Australia. J Viral Hepat. 2021;28(3):569-572.
Morris L, Selvey L, Williams O, Gilks C, Kvassy A, Smirnov A. Hepatitis C cascade of care at an integrated community facility for people who inject drugs. J Subst Abuse Treat. 2020;114:108025.
O'Sullivan M, Jones A-M, Gage H, et al. ITTREAT (Integrated Community Test-Stage-TREAT) hepatitis C service for people who use drugs: real-world outcomes. Liver Int. 2020;40(5):1021-1031.
Beiser ME, Smith K, Ingemi M, Mulligan E, Baggett TP. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int J Drug Policy. 2019;72:129-137.
Valerio H, Alavi M, Silk D, et al. Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage Study. Clin Infect Dis. 2020;73(1):e69-e78.
Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(11):754-767.
Bajis S, Grebely J, Cooper L, et al. Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: the LiveRLife homelessness study. J Viral Hepatitis. 2019;26(8):969-979.
Alavi M, Poustchi H, Merat S, et al. An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: the ENHANCE study. Int J Drug Policy. 2019;72:99-105.
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996-1005.e1.
Traeger MW, Pedrana AE, van Santen DK, et al. The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services. PLoS One. 2020;15(6):e0235445.
Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: final update of the series☆. J Hepatol. 2020;73(5):1170-1218.